Immune cells as a driver of cell non-autonomous aging

免疫细胞是细胞非自主衰老的驱动因素

• 批准号: 10554340
• 负责人: Laura Jane Niedernhofer
• 金额: $ 57.03万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10554340
• 关键词: Adoptive Transfer; Affect; Age; Age Months; Age Years; Aging; Agreement; Animals; Aorta; Apoptosis; Automobile Driving; Biological Assay; CDKN2A gene; Cardiovascular Diseases; Cell Differentiation process; Cell secretion; Cells; Cellular Stress; Characteristics; Chronic Disease; Cre lox recombination system; Cytometry; DNA Damage; DNA Repair Endonuclease; Data; Degenerative polyarthritis; Dementia; Diabetes Mellitus; Disease; ERCC1 gene; Elderly; Endothelial Cells; Enzymes; Event; Functional disorder; Generations; Genes; Goals; Health; Health Care Costs; Healthcare Systems; Hematopoietic; Histopathology; Holoenzymes; Homeostasis; Human; Immune; Immune response; Immune system; Impairment; In Vitro; Individual; Inflammation; Kidney; Knowledge; Life; Liver; Luciferases; Lung; Lymphopenia; Macrophage; Measurement; Measures; Mediating; Modeling; Morbidity - disease rate; Mus; Mutant Strains Mice; Natural Killer Cells; Organ; Parabiosis; Peripheral; Persons; Phenotype; Plasma; Play; Population; Proteinuria; Proteomics; Quality of life; Quantitative Reverse Transcriptase PCR; Regenerative capacity; Reporter; Risk; Role; Series; Serum; Signal Transduction; Solid; Sorting; Splenocyte; Syndrome; Time; Tissues; Transplantation; Validation; Wild Type Mouse; age related; aged; burden of illness; cell age; cell injury; cell type; emerging adult; experimental study; functional loss; granulocyte; healthspan; immune clearance; immune function; immunosenescence; in vivo; monocyte; mortality; mutant; normal aging; novel; perforin; premature; promoter; repaired; resilience; senescence; targeted treatment; therapeutic target; transcriptomics; young adult

Project Summary Aging and the chronic diseases associated with aging place a tremendous burden on our healthcare system and reduce quality of life for the elderly. As our world population ages dramatically over the next three decades, the burden will only increase. Hence, there is a great need to discover fundamental mechanisms of aging to develop rationale strategies for minimizing the impact of aging on our health and economy. There is general agreement that cell autonomous mechanisms contribute to aging. As cells accrue damage over time, they respond by triggering individual cell fate decisions (e.g., senescence and apoptosis) that ultimately disrupt tissue homeostasis and thereby increase risk of morbidity. However, more recently, there are numerous lines of evidence indicating that cell non-autonomous mechanisms are critically important as well. These cell non-autonomous mechanisms are likely much easier and safer to target therapeutically. Therefore identifying and characterizing these mechanisms is a priority. To ask if “aging” just one tissue in mice is sufficient to drive systemic aging, we generated a series of eight tissue-specific mutant animals in which DNA damage, senescence and tissue dysfunction were increased in only one cell type or tissue at a time. Our preliminary data indicate that “aged” immune cells play a key role in driving aging non-autonomously. Only in the hematopoietic cell mutant mice were non-targeted, peripheral tissues dramatically affected in the first year of life, showing increased senescence, inflammation and loss of homeostasis. The goal of this project is to fully define this novel mechanism of immune cell-mediated, non-autonomous aging in vivo. The aims of the project are to: 1. Determine the temporal order and extent of secondary senescence driven by an “aged” immune system. The specific immune and non-immune cell types with increased senescence will be identified by qRT-PCR and CyTOF at different mouse ages. The functional impact of the “aged” immune system on peripheral tissue homeostasis will be determined by measuring disease-specific endpoints and age-related histopathology. 2. Identify the immune cell type(s) that is most potent at driving systemic aging. This will be accomplished by transplanting splenocytes and isolated immune cell populations into young senescence reporter mice, followed by generation and characterization of cell-type specific mutant mice (e.g., T, B, NK cell or subpopulations). 3. Identify the mechanism by which “aged” immune cells drive systemic aging. This will be accomplished by serum transfer from the hematopoietic mutant mice into young senescence reporter mice followed by transcriptomic analysis of isolated immune cell populations to identify secreted factors. These putative pro-geronic factors will be validated by proteomics and functional validation. Completion of these aims will identify and characterize a novel mechanism(s) of cell non-autonomous aging driven by an aged immune system, which will lend itself to therapeutic targeting for extending human healthspan.

项目概要 老龄化以及与老龄化相关的慢性疾病给我们的医疗保健系统带来了巨大的负担 随着世界人口在未来三十年急剧老龄化，老年人的生活质量将会下降。 因此，非常需要发现衰老的基本机制来发展。 最大限度地减少老龄化对我们的健康和经济影响的基本原理策略。 人们普遍认为，细胞自主机制会导致细胞损伤。 随着时间的推移，它们通过触发个体细胞命运决定（例如衰老和细胞凋亡）来做出反应 最终破坏组织稳态并增加发病风险。然而，最近出现了这种情况。 大量证据表明细胞非自主机制也至关重要。 这些细胞非自主机制可能更容易、更安全地进行治疗。 识别和表征这些机制是当务之急，询问仅“老化”小鼠的一个组织是否就足够了。 为了驱动全身衰老，我们培育了一系列八种组织特异性突变动物，其中 DNA 损伤， 我们的初步数据显示，一次只有一种细胞类型或组织的衰老和组织功能障碍有所增加。 表明“衰老”的免疫细胞仅在造血系统中非自主地驱动衰老中发挥关键作用。 细胞突变小鼠在生命的第一年受到非靶向的外周组织的显着影响，显示 该项目的目标是全面定义这部小说。 免疫细胞介导的体内非自主衰老机制 该项目的目的是： 1. 确定由“老化”免疫系统驱动的继发性衰老的时间顺序和程度。 将通过 qRT-PCR 鉴定衰老增加的特定免疫和非免疫细胞类型，并 不同年龄小鼠的 CyTOF。“衰老”免疫系统对外周组织的功能影响。 体内平衡将通过测量疾病特异性终点和年龄相关的组织病理学来确定2。 确定最能有效驱动全身衰老的免疫细胞类型这一点将得以实现。 通过将脾细胞和分离的免疫细胞群移植到年轻的衰老报告小鼠中， 接下来是细胞类型特异性突变小鼠（例如 T、B、NK 细胞或 3. 确定“衰老”免疫细胞驱动全身衰老的机制。 通过将血清从造血突变小鼠转移到年轻的衰老报告小鼠中来完成 随后对分离的免疫细胞群进行转录组分析，以确定分泌因子。 推定的老年因素将通过蛋白质组学和功能验证进行验证。 完成这些目标将确定并表征细胞非自主衰老的新机制 由老化的免疫系统驱动，这将有助于延长人类健康寿命的治疗目标。